Regeneus’ Progenza stem cell therapy clears initial safety review – Proactive Investors Australia
Proactive Investors Australia |
Regeneus' Progenza stem cell therapy clears initial safety review
Proactive Investors Australia Regeneus' (ASX:RGS) off-the-shelf allogeneic stem cell treatment for knee osteoarthritis, Progenza, has enhanced its potential for commercialisation for the company after an encouraging review of safety data from an oversight committee in early trialling. |
